SK Life Science, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 101
- Market Cap
- -
Clinical Trials
84
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (81 trials with phase data)• Click on a phase to view related trials
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06453213
- Locations
- 🇺🇸
Arizona Neuroscience Research, Phoenix, Arizona, United States
🇺🇸Center For Neurosciences, Tucson, Arizona, United States
🇺🇸Clinical Trials Inc, Little Rock, Arkansas, United States
A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 mg Cenobamate Administered Orally
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05572255
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05388435
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
Investigate Efficacy and Safety of Carisbamate As Adjunctive Treatment for Seizures Associated with LGS in Children and Adults
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT05219617
- Locations
- 🇺🇸
Stanford University Hospital, Palo Alto, California, United States
🇺🇸University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸AdventHealth, Orlando, Florida, United States
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05067634
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
🇺🇸University of California Davis Health, Sacramento, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next